Wang Mengya, Liu Man, Ma Zegang
Department of Physiology, School of Basic Medicine, Institute of Brain Science and Disorders, Qingdao University, Qingdao, 266071, China.
Mol Biol Rep. 2023 May;50(5):4423-4433. doi: 10.1007/s11033-023-08395-4. Epub 2023 Mar 28.
Growing evidence indicates that cannabinoid type 2 (CB2) receptor activation inhibits neuroinflammation in the pathogenesis of Parkinson's disease (PD). Nonetheless, the precise mechanisms of CB2 receptor-mediated neuroprotection have not been fully elucidated. The differentiation of microglia from the M1 to M2 phenotype plays a vital role in neuroinflammation.
In the present study, we investigated the effect of CB2 receptor activation on the M1/M2 phenotypic transformation of microglia treated with 1-methyl-4-phenylpyridinium (MPP+). The M1 phenotype microglia markers, including inducible nitric oxide (iNOS), interleukin 6 (IL-6), and CD86, and the M2 phenotype microglia markers, including arginase-1 (Arg-1), IL-10, and CD206, were detected by western blots and flow cytometry. The levels of phosphoinositide-3-kinase (PI3K)/Akt and nuclear factor erythroid 2-related factor 2 (Nrf2) were determined by Western blots. Subsequent addition of Nrf2 inhibitors initially revealed the specific mechanism by which CB2 receptors affect phenotypic changes in microglia.
Our results showed that pretreatment with JWH133 significantly inhibited the MPP-induced up-regulation of M1 phenotype microglia markers. Meanwhile, JWH133 increased the levels of M2 phenotype microglia markers. JWH133-mediated effects were blocked by co-treatment with AM630. Mechanism studies found that MPP treatment downregulated PI3K, Akt phosphorylated proteins, and nuclear Nrf2 protein. JWH133 pretreatment promoted PI3K/Akt activation and facilitated nuclear translocation of Nrf2, which was reversed by the PI3K inhibitor. Further studies showed that Nrf2 inhibitors inverted the effect of JWH133 on microglia polarization.
The results indicate that CB2 receptor activation promotes MPP-induced microglia transformation from M1 to M2 phenotype through PI3K/Akt/Nrf2 signaling pathway.
越来越多的证据表明,2型大麻素(CB2)受体激活可抑制帕金森病(PD)发病机制中的神经炎症。然而,CB2受体介导的神经保护的确切机制尚未完全阐明。小胶质细胞从M1表型向M2表型的转变在神经炎症中起着至关重要的作用。
在本研究中,我们研究了CB2受体激活对用1-甲基-4-苯基吡啶离子(MPP+)处理的小胶质细胞M1/M2表型转化的影响。通过蛋白质免疫印迹法和流式细胞术检测M1表型小胶质细胞标志物,包括诱导型一氧化氮合酶(iNOS)、白细胞介素6(IL-6)和CD86,以及M2表型小胶质细胞标志物,包括精氨酸酶-1(Arg-1)、IL-10和CD206。通过蛋白质免疫印迹法测定磷酸肌醇-3-激酶(PI3K)/蛋白激酶B(Akt)和核因子红细胞2相关因子2(Nrf2)的水平。随后添加Nrf2抑制剂初步揭示了CB2受体影响小胶质细胞表型变化的具体机制。
我们的结果表明,用JWH133预处理可显著抑制MPP诱导的M1表型小胶质细胞标志物的上调。同时,JWH133增加了M2表型小胶质细胞标志物的水平。JWH133介导的效应被与AM630共同处理所阻断。机制研究发现,MPP处理下调了PI3K、Akt磷酸化蛋白和核Nrf2蛋白。JWH133预处理促进了PI3K/Akt激活并促进了Nrf2的核转位,这被PI3K抑制剂所逆转。进一步的研究表明,Nrf2抑制剂逆转了JWH133对小胶质细胞极化的影响。
结果表明,CB2受体激活通过PI3K/Akt/Nrf2信号通路促进MPP诱导的小胶质细胞从M1表型向M2表型转化。